JCR Pharmaceuticals, a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine, completed the acquisition of ArmaGen, a biopharmaceutical company. Financial terms were not disclosed. "JCR Pharmaceuticals is a very committed player in the field. Together with its solid in-house manufacturing capabilities it is a unique opportunity to leapfrog its innovative developments for the benefit of patients with desperate unmet medical need. The acquisition of ArmaGen is a synergy in its true sense and can catalyze the global market penetration of JCR's LSD portfolio," Mathias Schmidt, ArmaGen President and CEO.